Related Experiment Video

Updated: Aug 14, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

[The immunological status indices of monkeys inoculated with a meningococcal B vaccine]

L I Krasnoproshina, T V Kil'diushevskaia, T A Serova

    Zhurnal Mikrobiologii, Epidemiologii I Immunobiologii
    |March 1, 1991
    PubMed

    Insights

    A new enzyme immunoassay (EIA) method effectively measures antibodies to group B meningococcal vaccines. This study confirms the vaccine

    Area of Science:

    • Immunology
    • Microbiology
    • Vaccinology

    Background:

    • Group B meningococcal infections pose a significant public health threat.
    • Development of effective and safe vaccines against Neisseria meningitidis serogroup B is crucial.

    Purpose of the Study:

    • To develop and validate a method for determining bacterial antibodies against group B meningococci.
    • To assess the immunogenicity and safety of a group B meningococcal vaccine.

    Main Methods:

    • Enzyme immunoassay (EIA) was employed to quantify antibodies against protein, polysaccharide, and lipopolysaccharide antigens.
    • The glia migration test was utilized to evaluate vaccine safety by detecting anticerebral autoantibodies.

    Main Results:

    • The developed EIA method successfully determined antibodies to group B meningococcal vaccine antigens.
    • Immunization of monkeys with the group B vaccine led to an 8- to 10-fold increase in bactericidal antibodies.
    • The vaccine did not induce cytotoxic anticerebral antibodies, indicating a favorable safety profile.

    Conclusions:

    • The group B meningococcal vaccine demonstrates significant immunological activity by stimulating bactericidal antibodies.
    • The vaccine is deemed safe, as evidenced by the absence of anticerebral autoantibodies.
    • The EIA method is a reliable tool for assessing the immune response to group B meningococcal vaccines.

    More Related Videos

    Analysis of Simian Immunodeficiency Virus-specific CD8+ T-cells in Rhesus Macaques by Peptide-MHC-I Tetramer Staining06:25

    Analysis of Simian Immunodeficiency Virus-specific CD8+ T-cells in Rhesus Macaques by Peptide-MHC-I Tetramer Staining

    Published on: December 23, 2016

    Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery10:03

    Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

    Published on: November 5, 2019

    Related Concept Videos

    Vaccinations01:51

    Vaccinations

    Overview
    Bacterial Meningitis II: Pathophysiology01:26

    Bacterial Meningitis II: Pathophysiology

    Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...